InterVenn Biosciences Announces Positive Interim Clinical Trial Results and Appoints Biotech Veteran Klaus Lindpaintner, M.D. as Chief Scientific and Medical Officer
https://t.co/ptm3Z1nHHd
InterVenn Bio (@vennbio): mass spec + glycoproteomics + AI = diagnostics. Genoa Ventures is thrilled to announce our newest portfolio company at the intersection of biology x technology!
Today, we’re excited to add another healthcare company to the True portfolio with our investment in @vennbio and its co-founders @Aldocar and Lieza Danan https://t.co/tinTTf7rIs cc @adaugelli
Congratulations to @Aldocar and the entire @vennbio team. Computation is reimagining what can be done in life sciences and you are at the forefront. Excited for when you show your breakthrough tech to the world!
We are thrilled to announce our investment in @vennbio@Aldocar! @sarahcat21 shares more about the incredible founders & their differentiated approach to solving some of the most challenging problems in disease diagnosis with #AI, #massspec & #datascience. https://t.co/BhgzBdELG1
Computational proteomics will transform diagnostic and therapeutic development. I'm so excited to back the @vennbio as they pave the way in this exciting domain: https://t.co/9pradAzOUq
Computational proteomics will transform diagnostic and therapeutic development. I'm so excited to back the @vennbio as they pave the way in this exciting domain: https://t.co/9pradAzOUq